CD137L and CD4 T cells limit BCL6‐expressing pre‐germinal center B cell expansion and BCL6‐driven B cell malignancy
Sign Up to like & getrecommendations! Published in 2022 at "Immunology and Cell Biology"
DOI: 10.1111/imcb.12578
Abstract: Aberrant expression of the proto‐oncogene BCL6 is a driver of tumorigenesis in diffuse large B cell lymphoma (DLBCL). Mice overexpressing BCL6 from the B cell‐specific immunoglobulin heavy chain μ intron promoter (Iμ‐Bcl6Tg/+) develop B cell… read more here.
Keywords: cell; cd4 cells; cd4; cd137l ... See more keywords
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.608625
Abstract: B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells.… read more here.
Keywords: selective inhibitor; idelalisib; cll patients; cell malignancy ... See more keywords